Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients

NCT01455675 is registered in ClinicalTrials.gov with Mukoviszidose Institut gGmbH as lead sponsor.

NCT NCT01455675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients
Lead sponsor
Mukoviszidose Institut gGmbH
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
June 27, 2017
Enrollment
164 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis